Objective. To review the current state of the data on the use of cetuximab in head and neck
squamous cell carcinoma (HNSCC). Data Sources. The National Center for Biotechnology …

5513 Background: The goal of this study was to investigate the safety and efficacy of
cetuximab (Erbitux), an IgG1 monoclonal antibody targeting the EGFR, given in combination …

Purpose This was an open, randomized, multicenter, phase I/II study to investigate the safety
and tolerability of cetuximab in the first-line treatment of recurrent/metastatic squamous cell …

5507 Background: The majority of head and neck cancers overexpress the epidermal
growth factor receptor (EGFR), which is associated with aggressive tumor behavior and poor …

The administration of Cetuximab in combination with radiotherapy and chemotherapy has
shown clear survival improvements within the locally advanced and the relapsed/metastatic …

Cetuximab is typically administered on a weekly schedule for patients with recurrent or
metastatic head and neck squamous cell cancer (HNSCC). This study explores cetuximab …

Squamous cell carcinoma of the head and neck (SCCHN) is a prevalent disease both in the
United States and worldwide with an overall poor prognosis, in part due to limited activity of …

BACKGROUND AND PURPOSE: For locoregionally advanced HNSCC, chemoradiotherapy
with cisplatin or another platinum compound is considered as one of the standard treatment …

5537 Background: The epidermal growth factor receptor (EGFR) is expressed in nearly all
SCCHN and carries a strong prognostic significance, providing the rationale for using EGFR …

The Head and Neck Squamous Cell Cancer (HNSCC) is the most common type of head and
neck cancer (more than 90%), and all over the world more than a half million people have …